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Pathological phenotypes in inclusion body myopathy (IBM) associated 
with Paget disease of the bone (PDB), 
frontotemporal dementia (FTD) and 
amyotrophic lateral sclerosis (ALS) 
(IBMPFD/ALS) include defective 
autophagosome and endosome matura-
tion that result in vacuolation, weakness 
and muscle atrophy. The link between 
autophagy and IBMPFD/ALS pathobi-
ology has been poorly understood. We 
examined the AKT-FOXO3 and MTOR 
pathways to characterize the regulation 
of autophagy in IBMPFD/ALS mouse 
muscle. We identified a defect in MTOR 
signaling that results in enhanced 
autophagosome biogenesis. Modulating 
MTOR signaling may therefore be a via-
ble therapeutic target in IBMPFD/ALS.
Mutations in valosin containing protein 
(VCP) cause IBM associated with PDB, 
FTD and ALS. Prominent pathological 
phenotypes in VCP-associated disease 
include muscle weakness, which manifests 
in ~90% of patients. Moreover, vacuoles in 
IBMPFD/ALS patient skeletal muscle con-
tain autophagic and endocytic markers, 
such as SQSTM1/p62, LC3 and LAMP2.
That autophagosome and endosome mat-
uration is disrupted in IBMPFD/ALS is a 
serious concern because autophagic degra-
dation is critical for cellular homeostasis. 
We reasoned that defects in regulatory 
components, such as MTOR, which con-
trol autophagy, may contribute to patho-
genesis of IBMPFD/ALS. The R155H 
mutation is the most common IBMPFD 
mutation, and the majority of patients 
with IBMPFD/ALS bear VCP mutations 
in this residue. We made use of a mouse 
Rapamycin-induced autophagy aggravates pathology and weakness  
in a mouse model of VCP-associated myopathy
James K. Ching and Conrad C. Weihl*
Department of Neurology; Hope Center for Neurological Diseases; Washington University School of Medicine; St. Louis, MO USA
model that expresses the VCP-R155H 
mutation (VCP-RH) and recapitulates 
the myopathy component of IBMPFD/
ALS to characterize the regulation of the 
MTOR-autophagy pathway with respect 
to IBMPFD/ALS pathogenesis.
In an effort to further understand 
autophagic dysfunction in IBMPFD/
ALS, we examined the AKT-FOXO3 and 
MTOR pathways, which regulate autoph-
agy in skeletal muscle, and found that 
basal levels of phosphorylated AKTSer473 
and phosphorylated FOXO3Ser253 are nor-
mal in VCP-RH mice when compared 
with control mice and mice overexpressing 
the wild-type VCP transgene (VCP-WT 
mice). This observation was further con-
firmed by expression of downstream tar-
gets of FOXO3, which were found to be 
unchanged. However, when compared 
with control and VCP-WT mice, the levels 
of phosphorylated forms of direct targets 
of MTOR are reduced in two different 
VCP-RH mouse lines. These findings sug-
gest that MTOR signaling independent of 
AKT is defective in VCP-RH-expressing 
mouse muscle. Consistent with the fact 
that the MTOR direct targets EIF4EBP1 
and RPS6KB1/p70S6 kinase 1 regulate 
protein translation, we showed that basal 
global protein translation is reduced 
in VCP-RH-expressing mouse muscle. 
MTOR phosphorylates ULK1, inhibiting 
autophagosome formation. Diminished 
MTOR activity thus leads to an increase 
in autophagosome formation. By blocking 
autophagosome degradation in vivo with 
colchicine we confirmed that VCP-RH 
have enhanced autophagosome biogenesis 
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cells demonstrated that a potent VCP 
inhibitor, N2,N4-dibenzylquinazoline-
2,4-diamine (DBeQ), decreases both 
basal and nutrient-stimulated phos-
phorylation of MTOR targets similar to 
the effects of rapamycin. These findings, 
therefore, harmonize the in vivo data.
What are the chances and promises of 
restoring MTOR activity in IBMPFD/
ALS? The unexpected observation that 
MTOR dysfunction aggravates weakness 
and pathology in IBMPFD/ALS led to 
the proposition that restoration of MTOR 
activity in the setting of this disease may 
provide clues to therapeutic strategies. 
MTOR signaling requires translocation 
of MTOR to an acidic late endosomal 
compartment that contains RHEB, and 
the integrity of the endo-lysosomal system 
is necessary for this process. Inhibition of 
VCP activity and IBMPFD/ALS mutant 
VCP expression disrupts endo-lysosomal 
trafficking resulting in enlarged nonacidic 
late endosomes. To this end, we suspected 
that aberrant endo-lysosomes may fail to 
localize RHEB or redistribute MTOR 
upon nutrient stimulation. With this in 
mind, we transfected GFP or constitu-
tively active RHEB (caRheb-N153T-Flag) 
into U20S cells in the setting of DBeQ 
treatment and into stable VCP mutant 
cell lines including VCP-E578Q and 
VCP-R155H. Although restoration of the 
phosphorylation of RPS6 is less robust in 
the setting of DBeQ treatment and VCP-
E578Q, the restoration in VCP-R155H is 
comparable to the VCP-WT cells. These 
Having established that MTOR sig-
naling is defective in IBMPFD/ALS, we 
further inhibited MTOR by treating mice 
every other day for 21 d with rapamycin, 
a well-established autophagy inducer. 
Surprisingly, compared with control and 
VCP-WT mice, VCP-RH mice develop 
a further decrease in muscle strength, 
concomitant with a significant increase 
in serum creatine kinase levels as well as 
the number of vacuolated and atrophic 
fibers in response to rapamycin treatment. 
Similarly, autophagic substrates accu-
mulate more in VCP-RH mice following 
rapamycin treatment. These findings sug-
gest that chronic inhibition of MTOR, 
which results in enhanced autophagosome 
biogenesis, significantly worsens the 
already existing muscle degenerative phe-
notype in VCP-RH mice. MTOR activity 
is responsive to upstream environmental 
cues such as insulin or IGF1, nutrients, 
and energy changes. Which of these sig-
naling pathways underlies MTOR dys-
function in the setting of VCP mutations? 
To address this question, we showed that 
phosphorylation of AKT, a central player 
in the insulin signaling pathway, is stimu-
lated by insulin in both VCP-WT and 
VCP-RH mice. Furthermore, we found 
that activation of AMPK, a master sensor/
gauge for cellular energy, is unaffected in 
VCP-RH mice. However, treating mice 
with leucine i.p. after overnight starvation 
diminishes MTOR activation in VCP-RH 
mice compared with VCP-WT mice. 
Complementary experiments using U20S 
data, coupled with the fact that RHEB 
expression can increase the myofiber size 
when transiently expressed, established 
an emerging hypothesis that activation 
of MTOR by RHEB may be a viable and 
commendable therapeutic approach for 
IBMPFD/ALS. To further lend credence 
to this hypothesis, we demonstrated that 
transient expression of the caRheb-N153T-
Flag plasmid, by electroporation, into 
mouse tibialis anterior muscle is capable of 
activating MTOR and recovering myofi-
ber size in VCP-RH mice. Thus, our rec-
ommendations for future studies toward 
obtaining a finer picture of the outcome 
of restoring MTOR activity in IBMPFD/
ALS hinge on a closer inspection of pro-
longed RHEB expression to determine 
whether it can abrogate weakness, vacu-
olation and inclusion body formation in 
VCP-IBM mice.
In conclusion, our data, which pro-
vide evidence that MTOR signaling is 
disrupted in IBMPFD/ALS resulting in 
increased autophagosome biogenesis, con-
stitute a major leap forward in our under-
standing of the pathobiology of IBMPFD. 
Notably, chronic rapamycin treatment sig-
nificantly worsens the degenerative phe-
notype in VCP-RH mice. Thus, the data 
suggest a new role for VCP in autophagy, 
specifically, that VCP regulates MTOR 
signaling.
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